Women and atrial fibrillation
Atrial fibrillation (AF) remains a growing problem in the United States and worldwide, imposing a high individual and health system burden, including increased resource consumption due to repeated hospitalizations, stroke, dementia, heart failure, and death. This comprehensive review summarizes the...
Saved in:
Published in | Journal of cardiovascular electrophysiology Vol. 32; no. 10; pp. 2793 - 2807 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Atrial fibrillation (AF) remains a growing problem in the United States and worldwide, imposing a high individual and health system burden, including increased resource consumption due to repeated hospitalizations, stroke, dementia, heart failure, and death. This comprehensive review summarizes the most recent data on sex‐related differences in risks associated with AF. Women with AF have increased risk of stroke and death compared to men, and possible reasons for this disparity are explored. Women also continue to have worse symptoms and quality of life, and poorer outcomes with stroke prevention, as well as with rate and rhythm control management strategies. Many current rhythm control treatment strategies for AF, including cardioversion and ablation, are used less frequently in women as compared to men, whereas women are more likely to be treated with rate control strategies or antiarrhythmic drugs. Sex differences should be considered in treating women with AF to improve outcomes and women and men should be offered the same interventions for AF. We need to improve the evidence base to understand if variation in utilization of rate and rhythm control management between men and women represents health inequities or appropriate clinical judgement. |
---|---|
Bibliography: | Disclosures Anne B. Curtis: advisory board: Abbott, Janssen Pharmaceuticals, Novartis, Sanofi Aventis, and Milestone Pharmaceuticals; honoraria for speaking: Medtronic, Inc., Biotronik, Novartis, and Boston Scientific; data monitoring board: Medtronic, Inc. Gerald V. Naccarelli: consultant: Acesion, Omeicos, Janssen, Sanofi, and Milestone; research grant: Janssen. Andrea M. Russo: research trials (funding to hospital): BMS, Boehringer Ingelheim, Boston Scientific, Kestra, and Medilynx; Steering Committee, research: Apple, Boston Scientific (no financial reimbursement), and Medtronic; consulting: Medtronic. Annabelle S. Volgman: Apple Inc. Stock. Albert L. Waldo: consultant: Biosense Webster, Milestoms Pharmaceuticals, and Cardiac Insight; speaker: Pfizer and Bristol‐Myers Squib. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1045-3873 1540-8167 |
DOI: | 10.1111/jce.14838 |